President Bush vetoes stem cell research again

1 July 2007

US President George W Bush has used his veto power for only the third time since his inauguration in 2001, blocking legislation that would have authorized more federal funds for human embryonic stem cell research. It is the second time the Republican President has vetoed a stem cell bill and the decision was widely expected once the proposal failed to obtain the necessary two-thirds majority in the Senate (Marketletter April 16).

At present, federal government funding is prohibited for human embryonic stem cell lines created on or after August 9, 2001. The Stem Cell Research Enhancement Act of 2007 (S5) would have extended funding to human embryos originally created for fertility treatments and donated by patients, the Washington Post reports.

In other news, the Los Angeles Times reports that President Bush has issued an executive order which instructs the National Institutes of Health to research on stem cells "derived without creating a human embryo for research purposes or destroying, discarding or subjecting to harm a human embryo or fetus."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight